Cochrane · systematic review · CD009646
Creatine for Parkinson's disease
Xiao, Y, Luo, M, Luo, H, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Movement DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
2
current version
GRADE rated
2
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Creatine versus placebo for Parkinson's disease
Population: people with Parkinson's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
UPDRS motor score Creatine vs placebo | no estimate extracted | 2 studies · 194 participants | Low Downgraded: risk of bias, imprecision |
UPDRS ADL score Creatine vs placebo | 0.37 | 2 studies · 194 participants | Low Downgraded: risk of bias, imprecision |